Actively Recruiting

Phase Not Applicable
All Genders
Healthy Volunteers
ID04995341

Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care 2 and School Age Follow on Study (BabySTEPS2)

Led by Duke University · Updated on 2026-05-22

236

Participants Needed

2

Research Sites

N/A

Total Duration

On this page

Sponsors

D

Duke University

Lead Sponsor

U

University of Pennsylvania

Collaborating Sponsor

AI-Summary

What this Trial Is About

Retinopathy of prematurity (ROP) affects the development of the retina and its blood vessels in very preterm infants, potentially impacting their vision throughout life. Researchers are evaluating high-speed optical coherence tomography (OCT) technology at the bedside compared to traditional color photographs to identify early retinal abnormalities. The goal is to predict which infants may need treatment for ROP or face poor visual and neurological outcomes up to preschool age, aiming to improve early intervention and long-term care. The study involves four groups: children previously enrolled in a related study who will undergo follow-up neurodevelopmental and visual testing; infants at risk for ROP who will receive investigational bedside OCT imaging combined with earlier data; a subgroup receiving both investigational OCT and conventional retinal camera imaging to compare effectiveness and stress; and healthy adults and some children imaged during system development. The investigational OCT device is a portable, handheld system designed for non-contact, rapid retinal imaging in fragile infants. Participants will undergo imaging sessions at the bedside or under anesthesia, with assessments including retinal thickness, microanatomy, vascular severity, visual acuity, visual function, and neurodevelopmental scores at various ages up to five years. Researchers will also evaluate the stress and ease of imaging. Data from these assessments will help understand retinal changes linked to ROP and developmental outcomes. The study is ongoing with follow-up planned through 2027.

CONDITIONS

Brief Title

Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)

Who Can Participate

All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Children previously enrolled in BabySTEPS1 who consent to follow-up
  • Parent or legal guardian able and willing to consent for child participation between 4.5 and 5 years of age (Cohort 1)
  • Parent or legal guardian able and willing to consent for infant participation (Cohort 2 and 2c)
  • Infant or child undergoing clinically-indicated exam under anesthesia (Cohort 2)
  • Infant born at Duke Hospital with birth weight 6#8804;1000 grams and/or gestational age 20 0/7 to 28 6/7 weeks
  • Infant at high risk for ROP treatment regardless of birth weight or gestational age
  • Infant meeting American Academy of Pediatrics criteria for ROP screening at Duke Regional Hospital
  • Adults over 18 years old with or without eye pathology (Cohort 2)
Not Eligible

You will not qualify if you...

  • Participant or parent/legal guardian unwilling or unable to provide consent
  • Adult or infant with health or eye conditions preventing eye exam or retinal imaging (e.g., corneal opacity, cataract) (Cohort 2)
  • Infant with a health condition other than prematurity that profoundly impacts brain development (e.g., anencephaly) (Cohort 2)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 42 weeks post-menstrual age

Participants undergo bedside retinal imaging with investigational OCT and retinal photographs to gather detailed retinal microanatomy and microvasculature data relevant to vision and neurodevelopment.

Multiple imaging sessions during the monitoring period

Long-term Monitoring

Duration - Up to 5 years

Children previously enrolled are followed up for neurodevelopmental testing, visual acuity, and visual function testing along with investigational retinal imaging to assess long-term outcomes.

1 to 3 visits over several years depending on assessments

Trial Site Locations

Total: 2 locations

1

Duke University Eye Center

Durham, North Carolina, United States, 27705

Actively Recruiting

2

University of Pennsylvania, Center for Preventive Ophthalmology and Biostatistics

Philadelphia, Pennsylvania, United States, 19104

Not Yet Recruiting

Loading map...

Research Team

C

Cynthia A Toth, MD

M

Michelle N McCall, MCAPM, BA

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

4

Similar Trials

Drug Utilization Study for Eylea 40 mg/mL Using the PICLEO P...

Retinopathy of Prematurity

Actively Recruiting

1 location

Antiangiogenic Therapy With Bevacizumab in Retinopathy of Pr...

Retinopathy of Prematurity

Actively Recruiting

1 location

Clinical and Genetic Analysis of Retinopathy of Prematurity

Retinopathy of Prematurity

Actively Recruiting

5 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

LONGITUDINAL CHANGES IN THE OPTIC NERVE HEAD AND RETINA OVER TIME IN VERY YOUNG CHILDREN WITH FAMILIAL EXUDATIVE VITREORETINOPATHY.

Jonghyun Lee, Mays A El-Dairi, Du Tran-Viet...

https://pubmed.ncbi.nlm.nih.gov/29190238

Spectral-Domain OCT Findings of Retinal Vascular-Avascular Junction in Infants with Retinopathy of Prematurity.

Xi Chen, Shwetha Mangalesh, Alexandria Dandridge...

https://pubmed.ncbi.nlm.nih.gov/30506013

Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials.

Lois E H Smith, Ann Hellström, Andreas Stahl...

https://pubmed.ncbi.nlm.nih.gov/30543348